ADC Therapeutics reports Q3 2026 results, restructuring extends cash runway into 2029
The company detailed a PIPE and debt amendment completed in October, ASH 2026 abstracts for ZYNLONTA, and a Japan filing by partner Tanabe Pharma.
SEC filing
Latest
1 story